BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Angelicola S, Ruzzi F, Landuzzi L, Scalambra L, Gelsomino F, Ardizzoni A, Nanni P, Lollini PL, Palladini A. IFN-γ and CD38 in Hyperprogressive Cancer Development. Cancers (Basel) 2021;13:309. [PMID: 33467713 DOI: 10.3390/cancers13020309] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Gao L, Du X, Li J, Qin FX. Evolving roles of CD38 metabolism in solid tumour microenvironment. Br J Cancer 2023;128:492-504. [PMID: 36396822 DOI: 10.1038/s41416-022-02052-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Peng H, Wu X, Liu S, He M, Xie C, Zhong R, Liu J, Tang C, Li C, Xiong S, Zheng H, He J, Lu X, Liang W. Multiplex immunofluorescence and single-cell transcriptomic profiling reveal the spatial cell interaction networks in the non-small cell lung cancer microenvironment. Clin Transl Med 2023;13:e1155. [PMID: 36588094 DOI: 10.1002/ctm2.1155] [Reference Citation Analysis]
3 Britt AS, Huang C, Huang CH. Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth? Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.996554] [Reference Citation Analysis]
4 Theivanthiran B, Yarla N, Haykal T, Nguyen YV, Cao L, Ferreira M, Holtzhausen A, Al-Rohil R, Salama AKS, Beasley GM, Plebanek MP, DeVito NC, Hanks BA. Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti-PD-1 immunotherapy. Sci Transl Med 2022;14:eabq7019. [PMID: 36417489 DOI: 10.1126/scitranslmed.abq7019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 He T, Qiao Y, Yang Q, Chen J, Chen Y, Chen X, Hao Z, Lin M, Shao Z, Wu P, Xu F. NMI: a potential biomarker for tumor prognosis and immunotherapy. Front Pharmacol 2022;13:1047463. [PMID: 36506566 DOI: 10.3389/fphar.2022.1047463] [Reference Citation Analysis]
6 Wang YY, Li SY, Chen SQ, Wang LL, Han ZQ. Myeloid-derived Suppressor Cells Activate Liver Natural Killer Cells in a Murine Model in Uveal Melanoma. Curr Med Sci 2022. [PMID: 36245024 DOI: 10.1007/s11596-022-2623-3] [Reference Citation Analysis]
7 Xu X, Liu L, Wang H, Li W, Zou Y, Zeng Y, Yang Q, Bai D, Dai D. Engineered DBCO+PD-1 Nanovesicles Carrying 1-MT for Cancer-Targeted Immunotherapy. ACS Biomater Sci Eng 2022. [PMID: 36206367 DOI: 10.1021/acsbiomaterials.2c00639] [Reference Citation Analysis]
8 Shao X, Hua S, Feng T, Ocansey DKW, Yin L. Hypoxia-Regulated Tumor-Derived Exosomes and Tumor Progression: A Focus on Immune Evasion. IJMS 2022;23:11789. [DOI: 10.3390/ijms231911789] [Reference Citation Analysis]
9 Wang MX, Gao SY, Yang F, Fan RJ, Yang QN, Zhang TL, Qian NS, Dai GH. Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression? World J Clin Oncol 2022; 13(9): 729-737 [DOI: 10.5306/wjco.v13.i9.729] [Reference Citation Analysis]
10 Peng H, Wu X, Zhong R, Yu T, Cai X, Liu J, Wen Y, Ao Y, Chen J, Li Y, He M, Li C, Zheng H, Chen Y, Pan Z, He J, Liang W. Profiling Tumor Immune Microenvironment of Non-Small Cell Lung Cancer Using Multiplex Immunofluorescence. Front Immunol 2021;12:750046. [PMID: 34804034 DOI: 10.3389/fimmu.2021.750046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Sahin I, George A, Zhang S, Huntington KE, Ordulu Z, Zhou L, El-Deiry WS. Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab. Oncotarget 2021;12:2131-46. [PMID: 34676046 DOI: 10.18632/oncotarget.28086] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Mokhtari RB, Sambi M, Qorri B, Baluch N, Ashayeri N, Kumar S, Cheng HM, Yeger H, Das B, Szewczuk MR. The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. Cancers (Basel) 2021;13:3596. [PMID: 34298809 DOI: 10.3390/cancers13143596] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
13 Peng H, Wu X, Zhong R, Yu T, Cai X, Liu J, Wen Y, Ao Y, Chen J, Li Y, Zheng H, Chen Y, Pan Z, He J, Liang W. Profiling tumor immune microenvironment of non-small cell lung cancer using multiplex immunofluorescence.. [DOI: 10.1101/2021.05.28.446005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]